Lanx hauls in $15M for spinal devices

Colorado's Lanx has wrapped up a $15 million Series C, money the devicemaker will use to market its spinal fusion technologies around the globe. Lanx pulled in about $8.7 million of the total as of October, closing the difference in the ensuing months thanks to investors including Chicago Growth Partners and Goldman Sachs Private Equity Opportunities Fund. Now, Lanx plans to boost its sales infrastructure and expand the use of its Timberline Lateral Fusion System and Aspen MIS Fusion System. More

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.